The present study is a proof of concept, retrospective study of integrated NGS characterization of HER2 low tumors, evaluating the feasibility of using NGS for determination of the ERBB2 gene amplification in BC tumor specimens that have already undergone routine IHC for ER, PR, Ki67, and HER2 expression. The gene discussed is MKI67; the disease is breast cancer.